Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-19
Application #
6203077
Study Section
Project Start
1999-08-01
Project End
2002-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
19
Fiscal Year
1999
Total Cost
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Aslamy, Arianne; Oh, Eunjin; Olson, Erika M et al. (2018) Doc2b Protects ?-Cells Against Inflammatory Damage and Enhances Function. Diabetes 67:1332-1344
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Weitzel, Jeffrey N; Chao, Elizabeth C; Nehoray, Bita et al. (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816
Ghose, Jayeeta; Viola, Domenico; Terrazas, Cesar et al. (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948
Castanotto, Daniela; Zhang, Xiaowei; Alluin, Jessica et al. (2018) A stress-induced response complex (SIRC) shuttles miRNAs, siRNAs, and oligonucleotides to the nucleus. Proc Natl Acad Sci U S A 115:E5756-E5765
Awasthi, Sanjay; Tompkins, Joshua; Singhal, Jyotsana et al. (2018) Rlip depletion prevents spontaneous neoplasia in TP53 null mice. Proc Natl Acad Sci U S A 115:3918-3923
Röth, Daniel; Chiang, Abby J; Hu, Weidong et al. (2018) Two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation. FASEB J :fj201801848R
Li, Yi-Jia; Du, Li; Aldana-Masangkay, Grace et al. (2018) Regulation of miR-34b/c-targeted gene expression program by SUMOylation. Nucleic Acids Res 46:7108-7123
Maestrini, Davide; Abler, Daniel; Adhikarla, Vikram et al. (2018) Aging in a Relativistic Biological Space-Time. Front Cell Dev Biol 6:55
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60

Showing the most recent 10 out of 1396 publications